Navigation Links
ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
Date:1/30/2008

RANCHO CORDOVA, Calif., Jan. 30 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury, announced today it will report financial results for the fiscal second quarter ended December 31, 2007, on Wednesday, February 6, 2008.

Company's Conference Call and Webcast

Management will host a conference call Wednesday, February 6, 2008 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal second quarter financial results.

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 412-858-4600 outside the U.S. and referencing, "ThermoGenesis." Dr. William Osgood, Chief Executive Officer and Matthew Plavan, Chief Financial Officer will host the call to discuss the first quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins.

To listen to the audio webcast of the call during or after the event, please visit: http://www.thermogenesis.com/investor_relations/index.asp.

Replay

A replay of the conference call will be available two hours after the call for the following five business days by dialing 877-344-7529 within the U.S. or 412-317-0088 outside the U.S. and entering the following account number when prompted '385107'.

About ThermoGenesis Corp.

ThermoGenesis Corp. (http://www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

-- The BioArchive(R) System, an automated cryogenic device, is used by

cord blood stem cell banks in more than 25 countries for cryopreserving

and archiving cord blood stem cell units for transplant. GE Healthcare

is the non-exclusive global distribution partner for the BioArchive

System.

-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary, automated

device and companion sterile blood processing disposable for harvesting

stem cells from cord blood in a closed system. GE Healthcare is the

exclusive global distribution partner for the AXP AutoXpress Platform.

-- The CryoSeal(R) FS System, an automated device and companion sterile

blood processing disposable, is used to prepare fibrin sealants from

plasma in about an hour. We received FDA approval to market the

CryoSeal FS System in liver resection surgeries in July 2007. The

CryoSeal FS System has received the CE-Mark. From a marketing

perspective, the CE Mark is the European equivalent to an FDA approval,

in that it allows sales of the product throughout the European

community. Asahi Medical is the exclusive distributor for the CryoSeal

System in Japan and the Company markets through independent

distributors in Europe and South America.

-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood

processing disposable that prepares activated thrombin from a small

aliquot of plasma in less than 30 minutes. The CE-Marked TPD is

currently being marketed in Europe by Biomet, Inc., subsidiary Biomet

Biologics, Medtronic, Inc. and independent distributors.

This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2008, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2008. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.

Web site: http://www.thermogenesis.com

Contact: Investor Relations

+1-916-858-5107, or

ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
6. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
7. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
8. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
9. Helix BioPharma Corp. announces fiscal 2007 results
10. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
11. Helix BioPharma Corp. announces management changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Regen BioPharma Inc. (OTCQB: RGBPP) In ... Sciences a team of scientists in Guangzhou, China ... that expression of NR2F6 in patients with early cervical cancer ... patient,s cervical cancer tissue as well as in the normal ... an interesting study and the first that I am aware ...
(Date:12/7/2016)... ... December 07, 2016 , ... Proscia Inc., ... new service to enable rapid migration of large pathology data sets to the ... the factors limiting adoption of digital pathology. Proscia’s free massive dataset migrator makes ...
(Date:12/7/2016)... Francisco, CA (PRWEB) , ... ... ... leader uBiome is opening applications to an early access program for SmartBiome ... of metagenomic deep-sequencing with the simultaneous specific enrichment and detection of hundreds ...
(Date:12/6/2016)... Dec. 6, 2016 The American Botanical Council ... of arnica ( Arnica montana ) through ABC,s ... HerbMedPro database, a comprehensive, interactive online ... clinical research data on the uses and health ... Naturopathica, a wellness company with healing arts ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov 15, 2016 Research and Markets ... Forecast to 2021" report to their offering. ... ... 16.18 Billion by 2021 from USD 6.21 Billion in 2016, growing ... Growth of the bioinformatics market is driven by the growing ...
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):